Tobam Has $6.43 Million Stake in United Therapeutics Co. (NASDAQ:UTHR)

Tobam reduced its position in United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 52.0% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 18,222 shares of the biotechnology company's stock after selling 19,719 shares during the quarter. United Therapeutics comprises approximately 2.0% of Tobam's portfolio, making the stock its 13th biggest position. Tobam's holdings in United Therapeutics were worth $6,429,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently bought and sold shares of UTHR. USA Financial Formulas purchased a new stake in United Therapeutics in the 3rd quarter valued at approximately $33,000. Brooklyn Investment Group acquired a new position in shares of United Therapeutics during the 3rd quarter worth $33,000. Capital Performance Advisors LLP purchased a new stake in United Therapeutics during the third quarter worth about $82,000. MassMutual Private Wealth & Trust FSB lifted its position in shares of United Therapeutics by 31.9% during the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 240 shares of the biotechnology company's stock valued at $85,000 after acquiring an additional 58 shares during the period. Finally, Values First Advisors Inc. purchased a new stake in shares of United Therapeutics during the 3rd quarter worth approximately $90,000. 94.08% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of brokerages have recently weighed in on UTHR. Argus raised their price target on United Therapeutics from $360.00 to $400.00 and gave the company a "buy" rating in a research report on Thursday, October 31st. Oppenheimer boosted their target price on shares of United Therapeutics from $575.00 to $600.00 and gave the company an "outperform" rating in a research note on Thursday, October 31st. TD Cowen lifted their price target on shares of United Therapeutics from $350.00 to $400.00 and gave the stock a "buy" rating in a report on Monday, October 21st. LADENBURG THALM/SH SH boosted their price objective on shares of United Therapeutics from $319.00 to $344.00 and gave the company a "buy" rating in a research report on Thursday, October 31st. Finally, The Goldman Sachs Group increased their price target on United Therapeutics from $243.00 to $302.00 and gave the stock a "neutral" rating in a research note on Friday, November 1st. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating, ten have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, United Therapeutics presently has an average rating of "Moderate Buy" and a consensus target price of $382.08.

Insider Transactions at United Therapeutics

In other United Therapeutics news, COO Michael Benkowitz sold 10,000 shares of the company's stock in a transaction dated Monday, February 3rd. The shares were sold at an average price of $353.64, for a total value of $3,536,400.00. Following the completion of the transaction, the chief operating officer now owns 2,577 shares in the company, valued at approximately $911,330.28. This represents a 79.51 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP Paul A. Mahon sold 7,700 shares of United Therapeutics stock in a transaction that occurred on Thursday, December 5th. The shares were sold at an average price of $374.37, for a total value of $2,882,649.00. Following the sale, the executive vice president now directly owns 36,710 shares in the company, valued at approximately $13,743,122.70. This trade represents a 17.34 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 111,864 shares of company stock worth $41,036,365. 11.90% of the stock is currently owned by insiders.

United Therapeutics Stock Performance

Shares of NASDAQ UTHR traded up $9.33 during trading on Tuesday, reaching $354.97. The stock had a trading volume of 378,066 shares, compared to its average volume of 314,160. The firm's 50 day moving average price is $362.37 and its two-hundred day moving average price is $358.13. United Therapeutics Co. has a one year low of $210.64 and a one year high of $417.82. The stock has a market cap of $15.85 billion, a PE ratio of 15.59, a P/E/G ratio of 0.92 and a beta of 0.57.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.